Ispecimen vs Sera Prognostics
Ispecimen is the larger business, with $1.9m of revenue in fiscal 2025 against $81,000 for Sera Prognostics (23.8 times as much). Sera Prognostics grew faster (5.2% against -79.2%). Ispecimen kept more of each dollar of sales as profit: a net margin of -543.7% against -39417.3%. Ispecimen carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | IspecimenISPC, 2025 | Sera PrognosticsSERA, 2025 |
|---|---|---|
| Revenue | $1.9m | $81,000 |
| Revenue growth | -79.2% | 5.2% |
| Net income | −$10.5m | −$31.9m |
| Operating margin | -465.4% | -45066.7% |
| Net margin | -543.7% | -39417.3% |
| Return on equity | — | -51.8% |
| Free cash flow | −$4.2m | −$26.3m |
| Cash | $6.9m | $3.9m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 72 |
| Market value | $1.3m | $100m |
| Price vs our value range | — | — |
| Moat score | 26 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 52 sales |